Effects of fatty liver and related factors on the efficacy of combination antiviral therapy in patients with chronic hepatitis C

被引:42
|
作者
Wu, J
Chen, S [1 ]
Gui-Qiang, W
机构
[1] Harbin Med Univ, Affiliated Hosp 2, Dept Infect Dis, Harbin 150086, Peoples R China
[2] PeiKing Univ, Hosp 1, Dept Infect Dis, PeiKing, Peoples R China
关键词
fatty liver; genotype; hepatitis C; insulin; sustained virologic response;
D O I
10.1111/j.1478-3231.2006.01219.x
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Objective: Hepatic steatosis is a histological feature in patients with chronic hepatitis C (CHC) and adversely affects the virologic response rates to anti-hepatitis C virus (HCV) therapy. The aim of this study is to investigate whether the fatty liver and related factors have impact on the efficacy in CHC treated with peginterferon and ribavirin, and the associations between HCV genotyping and fatty liver. Methods: Ninety-eight patients received subcutaneously 180 mu g peginterferon alpha-2a once a week plus ribavirin. HCV genotypes and the levels of plasma insulin of patients were measured. Fatty liver was detected by B ultrasound. The body mass index (BMI), waist-to-hip ratio (WHR) and homeostasis model assessment of insulin resistance (HOMA-IR) were calculated. Results: Among 98 CHC patients, 38 (38.8%) were infected with genotype 1; 44 (44.9%) with genotype 2; 13 (13.3%) with genotype 3; 3 (3.0%) with indeterminate genotype. The prevalence of fatty liver was 10.5%, 11.4%, 38.5% in patients infected with HCV genotype 1, 2, 3, respectively, which suggested that the distribution of fatty liver in different HCV genotypes was imbalanced (chi(2)=6.758, P=0.034). In univariate analysis, the efficacy of combination therapy was significantly associated with BMI (P=0.011), WHR (P=0.024), the levels of plasma insulin (P=0.001), genotype (P=0.036), presence of fatty liver (P=0.028), treatment dosage and duration (P=0.012) and HOMA-IR (P=0.002). With binary logistic regression analysis, the plasma insulin levels and HOMA-IR showed independent predictors to the efficacy of antiviral therapy. Conclusion: The prevalence of fatty liver in HCV genotype 3 was markedly higher than that of other genotypes. The BMI, WHR, the levels of plasma insulin, genotype, presence of fatty liver, treatment dosage and duration and HOMA-IR were associated with the sustained virologic response. The level of plasma insulin and HOMA-IR were independent factors for predicting effect of antiviral therapy.
引用
收藏
页码:166 / 172
页数:7
相关论文
共 50 条
  • [21] Predictive factors associated with hepatitis C antiviral therapy response
    Lourianne Nascimento Cavalcante
    André Castro Lyra
    World Journal of Hepatology, 2015, (12) : 1617 - 1631
  • [22] Predictive factors associated with hepatitis C antiviral therapy response
    Cavalcante, Lourianne Nascimento
    Lyra, Andre Castro
    WORLD JOURNAL OF HEPATOLOGY, 2015, 7 (12) : 1617 - 1631
  • [23] Applicability, tolerability and efficacy of preemptive antiviral therapy in hepatitis C-infected patients undergoing liver transplantation
    Shergill, AK
    Khalili, M
    Straley, S
    Bollinger, K
    Roberts, JP
    Ascher, NA
    Terrault, NA
    AMERICAN JOURNAL OF TRANSPLANTATION, 2005, 5 (01) : 118 - 124
  • [24] Independent Risk Factors for Hepatocellular Carcinoma Recurrence after Direct-Acting Antiviral Therapy in Patients with Chronic Hepatitis C
    Ahn, Young-Hwan
    Lee, Heirim
    Kim, Do Young
    Lee, Hye Won
    Yu, Su Jong
    Cho, Young Youn
    Jang, Jeong Won
    Jang, Byoung Kuk
    Kim, Chang Wook
    Kim, Hee Yeon
    Park, Hana
    Cho, Hyo Jung
    Park, Bumhee
    Kim, Soon Sun
    Cheong, Jae Youn
    GUT AND LIVER, 2021, 15 (03) : 410 - 419
  • [25] Efficacy and Safety of Direct Acting Antiviral Therapy for Chronic Hepatitis C in Thalassemic Children
    Padhi, Shivadatta
    Maharshi, Sudhir
    Gupta, Gaurav K.
    Garg, Kapil
    Nijhawan, Sandeep
    JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY, 2018, 40 (07) : 511 - 514
  • [26] Efficacy and Safety of Combination Therapy of Natural Human Interferon Beta and Ribavirin in Chronic Hepatitis C patients
    Arase, Yasuji
    Suzuki, Yoshiyuki
    Suzuki, Fumitaka
    Matsumoto, Naoki
    Akuta, Norio
    Imai, Norihiro
    Seko, Yuya
    Sezaki, Hitomi
    Kawamura, Yusuke
    Kobayashi, Masahiro
    Hosaka, Tetsuya
    Saito, Satoshi
    Ikeda, Kenji
    Kobayashi, Mariko
    Kumada, Hiromitsu
    INTERNAL MEDICINE, 2011, 50 (19) : 2083 - 2088
  • [27] Predictive factors for efficacy of interferon therapy in chronic hepatitis type C
    Ishibashi, K
    Kashiwagi, T
    Ito, A
    Tanaka, Y
    Nagata, T
    Tamaki, J
    Azuma, M
    Kishida, Y
    Yoshida, A
    Hikiji, K
    HEPATO-GASTROENTEROLOGY, 1995, 42 (05) : 535 - 541
  • [28] Efficacy of Combination Therapy Sofosbuvir, Daclatasvir and Ribavirin in Patients of Hepatitis C
    Quddus, Muhammad Abdul
    Zaib, Jahangir
    Munawar, Rukhsana
    Siddiq, Shazia
    Tahir, Rabia
    Kiani, Rizwan Saeed
    PAKISTAN JOURNAL OF MEDICAL & HEALTH SCIENCES, 2021, 15 (09): : 2823 - 2825
  • [29] Antiviral therapy for chronic hepatitis C viral infection
    Sherlock, S
    JOURNAL OF HEPATOLOGY, 1995, 23 : 3 - 7
  • [30] Accessibility to Oral Antiviral Therapy for Patients with Chronic Hepatitis C in the United States
    Saab, Sammy
    Jimenez, Melissa
    Fong, Tiffany
    Wu, Crystal
    Bau, Sherona
    Jamal, Zoha
    Grotts, Jonathan
    Elashoff, David
    JOURNAL OF CLINICAL AND TRANSLATIONAL HEPATOLOGY, 2016, 4 (02) : 76 - 82